MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept) for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback